Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-07-25
DOI
10.3389/fonc.2018.00285
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
- (2018) Colin E. Correnti et al. LEUKEMIA
- Development of MGD007, a gpA33 x CD3 bispecific DART® protein for T-cell immunotherapy of metastatic colorectal cancer
- (2018) Paul A Moore et al. MOLECULAR CANCER THERAPEUTICS
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
- (2018) Z. Wu et al. PHARMACOLOGY & THERAPEUTICS
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination
- (2017) Arash Memarnejadian et al. JOURNAL OF IMMUNOLOGY
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells
- (2017) Gap Ryol Lee MEDIATORS OF INFLAMMATION
- Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
- (2017) Elie Dheilly et al. MOLECULAR THERAPY
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'
- (2017) Paul J. Carter et al. NATURE REVIEWS DRUG DISCOVERY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
- (2017) Andres Lopez-Albaitero et al. OncoImmunology
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
- (2016) Friederike Braig et al. BLOOD
- A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
- (2016) N. Haense et al. BMC CANCER
- Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing -Irradiation
- (2016) M. Hettich et al. CANCER RESEARCH
- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- The use of CrossMAb technology for the generation of bi- and multispecific antibodies
- (2016) Christian Klein et al. mAbs
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
- (2016) Nina Deppisch et al. Oncotarget
- Evolving role of cetuximab in the treatment of colorectal cancer
- (2016) Gunter Schuch Cancer Management and Research
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
- (2015) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunotherapy in Tumors
- (2015) Sebastian Kobold et al. Deutsches Arzteblatt International
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
- (2015) Tao Dao et al. NATURE BIOTECHNOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
- (2015) G S Laszlo et al. Blood Cancer Journal
- Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
- (2015) Jens Schreiner et al. OncoImmunology
- A review of blinatumomab, a novel immunotherapy
- (2015) Matthew J Newman et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
- (2014) T. T. Junttila et al. CANCER RESEARCH
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- Antitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies?
- (2013) J. Maher et al. CANCER RESEARCH
- SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
- (2013) Kavita M Dhodapkar et al. OncoImmunology
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
- (2009) Mohammad Tabrizi et al. AAPS Journal
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10
- (2009) J. S. Klein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?
- (2009) Christopher J. Horvath et al. TOXICOLOGIC PATHOLOGY
- Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels
- (2008) Michael Stanglmaier et al. INTERNATIONAL JOURNAL OF CANCER
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started